Brief: Aridis Pharmaceuticals Covid Mab Ar-712 Neutralizes Sars-Cov-2 Delta Variant

Aridis Pharmaceuticals

12/07/2021 21:07

July 12 (Reuters) - Aridis Pharmaceuticals Inc  ARDS.O :
    * ARIDIS PHARMACEUTICALS COVID MAB AR-712 NEUTRALIZES
SARS-COV-2
DELTA VARIANT
    * ARIDIS PHARMA - TEXAS BIOMEDICAL RESEARCH INSTITUTE AND
ARIDIS'
DATA CONFIRMED AR-712 BINDS TO AND NEUTRALIZES DELTA VARIANT OF
SARS-COV-2 VIRUS
    * ARIDIS PHARMA - BINDING ANALYSIS PROJECTS ABILITY OF
AR-712 TO
BIND TO ALL VARIANTS ON CDC'S VARIANTS OF INTEREST AND VARIANTS
OF CONCERN LISTS
    * ARIDIS PHARMACEUTICALS INC - REMAINS ON TRACK TO FINALIZE
PHASE
1/2/3 DESIGN FOR THIS PROGRAM AND INITIATE CLINICAL STUDY IN 2H
2021

Source text for Eikon:  ID:nPnc7vRbRa 
Further company coverage:  ARDS.O 

 ((Reuters.Briefs@thomsonreuters.com;))